CN107467667A - A kind of compound preparation containing two kinds of unrighted acids and sialic acid - Google Patents
A kind of compound preparation containing two kinds of unrighted acids and sialic acid Download PDFInfo
- Publication number
- CN107467667A CN107467667A CN201710582418.1A CN201710582418A CN107467667A CN 107467667 A CN107467667 A CN 107467667A CN 201710582418 A CN201710582418 A CN 201710582418A CN 107467667 A CN107467667 A CN 107467667A
- Authority
- CN
- China
- Prior art keywords
- compound preparation
- sialic acid
- kinds
- unrighted acids
- preparation containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 109
- 150000001875 compounds Chemical class 0.000 title claims abstract description 91
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 65
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 65
- 239000002253 acid Substances 0.000 title claims abstract description 35
- 150000007513 acids Chemical class 0.000 title claims abstract description 32
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 25
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 25
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960001231 choline Drugs 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 8
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 21
- 235000013793 astaxanthin Nutrition 0.000 claims description 21
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 21
- 229940022405 astaxanthin Drugs 0.000 claims description 21
- 239000001168 astaxanthin Substances 0.000 claims description 21
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 235000010445 lecithin Nutrition 0.000 claims description 16
- 229940067606 lecithin Drugs 0.000 claims description 16
- 239000000787 lecithin Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 14
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 7
- 229960003080 taurine Drugs 0.000 claims description 7
- 229940050168 zinc lactate Drugs 0.000 claims description 7
- 235000000193 zinc lactate Nutrition 0.000 claims description 7
- 239000011576 zinc lactate Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 abstract description 20
- 235000016709 nutrition Nutrition 0.000 abstract description 19
- 230000002028 premature Effects 0.000 abstract description 17
- 230000035764 nutrition Effects 0.000 abstract description 15
- 230000018109 developmental process Effects 0.000 abstract description 13
- 235000020256 human milk Nutrition 0.000 abstract description 10
- 210000004251 human milk Anatomy 0.000 abstract description 10
- 230000004641 brain development Effects 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 4
- 230000008131 children development Effects 0.000 abstract description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 35
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 35
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 35
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 35
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 34
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 33
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 17
- 239000003513 alkali Substances 0.000 description 11
- 235000013372 meat Nutrition 0.000 description 11
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 6
- 229960004203 carnitine Drugs 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- 210000001218 blood-brain barrier Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000001202 rhombencephalon Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- -1 DHA Chemical compound 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000015015 brainstem development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000005480 straight-chain fatty acid group Chemical group 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is related to a kind of compound preparation of infant development, by weight percentage, compound preparation includes 5%~15%DHA, 10%~20%ARA, 2%~8% sialic acid, 2%~5% phosphatidylserine, 1%~2% antioxidant, 1%~3% acetyl-L-carnitine, 1%~2% choline and auxiliary material.Compared with prior art, the present invention proposes the essential elements of a kind of compound preparation, predominantly the neonatal supplement brain development of premature and breast milk deficiency, ensures infant brain normal development, avoids because brain defect caused by nutrition is certain.
Description
Technical field
It is related to a kind of compound preparation of infant development, especially a kind of compound preparation of baby's brain development.
Background technology
Docosahexaenoic acid, i.e. DHA, it is the straight chain fatty acid containing 22 carbon atoms and 6 double bonds, is that human body must
A kind of polyunsaturated fatty acid needed, but growing amount is relatively low, is mainly supplemented by food.DHA is the important structure of brain cell film
Into composition, the formation and development of brain cell are participated in, the formation of extension and new projection to nerve cell axons plays an important role, can
The normal physiological activity of nerve cell is maintained, promotes the synthesis of nerve cell protein, participates in human thinking and memory forming process.
Arachidonic acid, scientific name eicosatetraenoic acid, both ARA, a carbon-oxygen double bond, was advanced insatiable hunger containing four carbon-to-carbon double bonds
And aliphatic acid.It is distributed widely in the animal kingdom, can be synthesized in human body by linoleic acid.Belong to essential fatty acid in child's period ARA.But
It is that the interior synthesis ARA of dotey's body ability is relatively low in infantile period, therefore the dotey for being in anthropometic golden period comes
Say, certain ARA is provided in food, the development of its physique can be more beneficial for.Hair of the ARA shortage for human tissue organ
Educate, especially there may be serious harmful effect for brain and nervous system development.Generation of the sialic acid in brain and nervous system
With very important effect is played in development.Enough sialic acids supply the normal development for low birth weight children's brain function
It is even more important.After baby due, the sialic acid content in breast milk can ensure their normal development, but give a birth stepmother's parent
Interior Sialic Acid Level is over time into downward trend.Therefore, the pregnancy period and it is pregnant after persistently take in enough sialic acids, can be with
Help maintains internal Sialic Acid Level.Moreover, the content of sialic acid also has obvious correlation with DHA content,
This shows that it is very likely relevant with the brain structure of baby and brain function development, may be both beneficial to early stage brain growth.
For premature and newborn baby, their bodies are not developed also completely, can not synthesize DHA, ARA in vivo
With sialic acid fully relies on breast milk and taken a tonic or nourishing food to build up one's health, can be to cerebral neural development if it can not supplement DHA, ARA and sialic acid
Cause ill effect.But mother's milk volume of premature and part newborn baby and inadequate, this is with regard to needing to pass through
Other means carry out the supplement of nutriment.
The content of the invention
The present invention is directed to deficiency of the prior art, there is provided a kind of answering containing two kinds of unrighted acids and sialic acid
The essential elements of the neonatal supplement brain development of square preparation, predominantly premature and breast milk deficiency, is ensureing infant brain just
Often development, avoid because brain defect caused by nutrition is certain.
In order to solve the above-mentioned technical problem, the present invention is addressed by following technical proposals：One kind contains two kinds of insatiable hungers
With aliphatic acid and the compound preparation of sialic acid, by weight percentage, compound preparation includes 5%~15%DHA, and 10%~20%
ARA, 2%~8% sialic acid, 2%~5% phosphatidylserine, 1%~2% antioxidant, the left-handed meat of 1%~3% acetyl
Alkali, 1%~2% choline and auxiliary material.
In above-mentioned technical proposal, it is preferred that also including 1%~3% zinc lactate and 1%~5% taurine.
In above-mentioned technical proposal, it is preferred that be, described auxiliary material be lecithin, beeswax, gelatin, glycerine, water one kind or
A variety of mixtures.
In above-mentioned technical proposal, it is preferred that described antioxidant is vitamin A, vitamin C, vitamin E, astaxanthin
One kind.
In above-mentioned technical proposal, it is preferred that described antioxidant is astaxanthin.
In above-mentioned technical proposal, it is preferred that when described auxiliary material is lecithin, compound preparation is powdery.
In above-mentioned technical proposal, it is preferred that when described auxiliary material is water, compound preparation is the aqueous solution.
In above-mentioned technical proposal, it is preferred that when described auxiliary material is a variety of mixtures, compound preparation is pasty state or cream
Body.
In above-mentioned technical proposal, it is preferred that with weight ratio meter, DHA and ARA content is 1 in compound preparation：2.
In above-mentioned technical proposal, it is preferred that by weight percentage, compound preparation includes 10%DHA, 20%ARA, 4%
Sialic acid, 2.5% phosphatidylserine, 1% antioxidant, 1% acetyl-L-carnitine, 1.5% choline and 60% auxiliary material.
DHA, ARA and sialic acid are the indispensable necessary nutrient matter of baby's brain development, and these nutriments are main
There is provided by breast milk, but the breast milk of premature and part mother baby are insufficient, it is impossible to sufficient nutrition is supplemented for baby, once
The defects of DHA, ARA and saliva subacidity will result in baby's brain, influence all one's life of baby.This compound preparation can replace
The nutritional ingredient of breast milk deutocerebral region development, according to premature, neonatal, baby in March-June, the different business of baby in June-December
Absorption mode has the diversified forms such as pulvis, aqua, paste, lotion.The main component of this compound preparation is DHA, ARA, saliva
Liquid acid, phosphatidylserine, antioxidant, acetyl-L-carnitine, choline, zinc lactate and ox can also be added according to being actually needed
Sulfonic acid.This compound preparation difference maximum with existing nutritional agents is in order to avoid premature's digestive system imperfection can not
Absorb and develop pulvis and aqua, pulvis and aqua can carry out nutritional supplementation by way of injection to premature.It is known
, compared to adult, the blood-brain barrier effect of baby is weaker, and some bulky grain molecules can also enter brain by blood-brain barrier, this
DHA in compound preparation, ARA, sialic acid, phosphatidylserine, acetyl-L-carnitine all can easily pass through blood-brain barrier
Material, antioxidant can also select draw from blood by the astaxanthin of blood-brain barrier, premature and neonatal brain
The ability for taking choline is extremely strong, can directly allow these nutrients to be applied to brain rapidly by intravenous injection, promote brain
Portion develops, and can not absorb battalion this avoid premature or part neonate's digestive system imperfection or with disease of digestive system
The problem of supporting material.For the baby in March-June, can be supplemented by feed, the baby in this stage can stablize
Dietary intake, without particular/special requirement without heavy dose of supplement brain nutrition thing, can be by aqua and paste now
Adequate nutrition element is supplemented in the baby in March-June.To being fed by paste and lotion for baby in June-December, now
Compound preparation can also add zinc lactate and taurine, more fully be supplemented.Because DHA, ARA, taurine, zinc are mended simultaneously
Brain development can preferably be promoted by filling, while DHA and ARA ratios are 1 in this compound preparation：2, in this ratio baby couple
DHA and ARA absorption is more thorough, and brain development facilitation is become apparent from.
Compared with prior art, the present invention proposes a kind of compound preparation, and predominantly premature's and breast milk deficiency is first
Raw youngster supplements the essential elements of brain development, ensures infant brain normal development, avoids because brain caused by nutrition is certain lacks
Fall into.
Embodiment
For the objects, technical solutions and advantages of the present invention are more clearly understood, the present invention is described in more detail.
Embodiment 1：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 5%DHA, 10%ARA, 2% sialic acid, 2% phosphatidylserine, 1% astaxanthin, 1% acetyl-L-carnitine,
1% choline and 78% lecithin.The compound preparation of the present embodiment is pulvis.
Embodiment 2：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 7%DHA, 14%ARA, 3% sialic acid, and 3% phosphatidylserine, 1.5% astaxanthin, 1.5% acetyl are left-handed
Carnitine, 2% choline and 68% lecithin.The compound preparation of the present embodiment is pulvis.
Embodiment 3：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 2% sialic acid, 3% phosphatidylserine, 2% astaxanthin, the left-handed meat of 1% acetyl
Alkali, 2% choline and 60% lecithin.The compound preparation of the present embodiment is pulvis.
Embodiment 4：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 8% sialic acid, 5% phosphatidylserine, 2% vitamin A, the left-handed meat of 3% acetyl
Alkali, 2% choline and 50% lecithin.The compound preparation of the present embodiment is pulvis.
Embodiment 5：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 7%DHA, 14%ARA, 4% sialic acid, and 2.5% phosphatidylserine, 1.5% astaxanthin, 2% acetyl are left-handed
Carnitine, 1% choline and 68% lecithin.The compound preparation of the present embodiment is pulvis.
Embodiment 6：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 4% sialic acid, 2.5% phosphatidylserine, 1% astaxanthin, the left-handed meat of 1% acetyl
Alkali, 1.5% choline and 60% lecithin.The compound preparation of the present embodiment is pulvis.
Embodiment 7：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 5%DHA, 10%ARA, 2% sialic acid, 2% phosphatidylserine, 1% astaxanthin, 1% acetyl-L-carnitine,
1% choline and 78% water.The compound preparation of the present embodiment is aqua.
Embodiment 8：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 7%DHA, 14%ARA, 3% sialic acid, and 3% phosphatidylserine, 1.5% astaxanthin, 1.5% acetyl are left-handed
Carnitine, 2% choline and 68% water.The compound preparation of the present embodiment is aqua.
Embodiment 9：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 2% sialic acid, 3% phosphatidylserine, 2% astaxanthin, the left-handed meat of 1% acetyl
Alkali, 2% choline and 60% water.The compound preparation of the present embodiment is aqua.
Embodiment 10：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 8% sialic acid, 5% phosphatidylserine, 2% vitamin A, the left-handed meat of 3% acetyl
Alkali, 2% choline and 50% water.The compound preparation of the present embodiment is aqua.
Embodiment 11：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 7%DHA, 14%ARA, 4% sialic acid, and 2.5% phosphatidylserine, 1.5% astaxanthin, 2% acetyl are left-handed
Carnitine, 1% choline and 68% water.The compound preparation of the present embodiment is aqua.
Embodiment 12：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 4% sialic acid, 2.5% phosphatidylserine, 1% astaxanthin, the left-handed meat of 1% acetyl
Alkali, 1.5% choline and 60% water.The compound preparation of the present embodiment is aqua.
Embodiment 13：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 2% sialic acid, 3% phosphatidylserine, 2% astaxanthin, the left-handed meat of 1% acetyl
Alkali, 2% choline and 20% lecithin, 10% beeswax, 10% glycerine, 20% water.The compound preparation of the present embodiment is paste body.
Embodiment 14：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 8% sialic acid, 5% phosphatidylserine, 2% astaxanthin, the left-handed meat of 3% acetyl
Alkali, 2% choline and 20% lecithin, 5% beeswax, 5% glycerine, 20% water.The compound preparation of the present embodiment is paste body.
Embodiment 15：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 7%DHA, 14%ARA, 4% sialic acid, and 2.5% phosphatidylserine, 1.5% astaxanthin, 2% acetyl are left-handed
Carnitine, 1% choline and 20% lecithin, 10% beeswax, 10% glycerine, 26% water.The compound preparation of the present embodiment is paste body.
Embodiment 16：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 2% sialic acid, 3% phosphatidylserine, 2% astaxanthin, the left-handed meat of 1% acetyl
Alkali, 2% choline, 1% zinc lactate, 1% taurine and 10% lecithin, 10% beeswax, 8% gelatin, 10% glycerine, 20% water.
The compound preparation of the present embodiment is lotion.
Embodiment 17：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 10%DHA, 20%ARA, 8% sialic acid, 5% phosphatidylserine, 2% astaxanthin, the left-handed meat of 3% acetyl
Alkali, 2% choline, 3% zinc lactate, 5% taurine and 10% lecithin, 5% beeswax, 12% gelatin, 5% glycerine, 10% water.
The compound preparation of the present embodiment is lotion.
Embodiment 18：A kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is by weight percentage, multiple
Square preparation includes 7%DHA, 14%ARA, 4% sialic acid, and 2.5% phosphatidylserine, 1.5% astaxanthin, 2% acetyl are left-handed
Carnitine, 1% choline, 2% zinc lactate, 3% taurine and 10% lecithin, 10% beeswax, 11% gelatin, 10% glycerine, 20%
Water.The compound preparation of the present embodiment is lotion.
| Embodiment | Premature | Number | Average daily intake | Take in number of days | Intake terminates rear mean time cranial capacity |
| Embodiment 1 | 34 weeks | 1 | 2ml | 45 | 376g |
| Embodiment 2 | 34 weeks | 1 | 2ml | 45 | 382g |
| Embodiment 3 | 35 weeks | 1 | 2ml | 40 | 387g |
| Embodiment 4 | 35 weeks | 1 | 2ml | 40 | 386g |
| Embodiment 5 | 36 weeks | 1 | 2ml | 35 | 386g |
| Embodiment 6 | 36 weeks | 1 | 2ml | 35 | 382g |
Table 1- premature takes the mature hindbrain capacities chart of this compound preparation embodiment 1 to 6
Premature is non-breastfeeding in table 1, and this compound preparation is not premature's sole nutrition intake means, but with
Other nutrients are taken in jointly, and this compound preparation is mainly that newborn baby development provides nutrition.Wherein in premature's digestive system
By intravenous injection before not developing completely, taken in after feeding by feeding.Intravenous injection and feed intake are required for passing through it
His solvent dissolves to this compound preparation pulvis or aqua.
Table 2- neonate takes 7 to 12 6 months hindbrain capacities charts of this compound preparation embodiment
Neonate is non-breastfeeding in table 2, and this compound preparation is not neonate's sole nutrition intake means, but with
Other nutrients are taken in jointly, and this compound preparation is mainly that newborn baby development provides nutrition.All carried out in table 2 by feeding
The intake of nutrition.Feed intake is required for dissolving this compound preparation pasty state or aqua by other solvents.
| Embodiment | Number | Average daily intake | Take in number of days | Intake terminates rear mean time cranial capacity |
| Embodiment 16 | 2 | 5ml | 180 | 995g |
| Embodiment 17 | 3 | 5ml | 180 | 977g |
| Embodiment 18 | 2 | 5ml | 180 | 982g |
3-6 month baby clothes 16 to 18 6 months hindbrain capacities charts of this compound preparation embodiment of table
6 months babies are non-breastfeeding in table 3, and this compound preparation is not 6 months baby's sole nutrition intake means,
But taken in jointly with other nutrients, this compound preparation is mainly that 6 months developing infant brains provide nutrition.It is all logical in table 3
Cross the intake that feed carries out nutrition.Feed intake is required for dissolving this compound preparation aqua by other solvents, pasty state
Either paste is fed after directly can feeding or dissolve.
There is the offer of this compound preparation in supply of the table 1 into table 3 to brain business material, other nutrients provide other
The nutritional ingredient to sustain life, largely it is not related to the development of brain.It can be obtained by table 1 to 3, this compound preparation can substitute mother
Brain growth composition in breast, taking in this compound preparation can allow brain development good, and the compound baby of cranial capacity each stage is averaged
Standard, part index number are higher than average.This compound preparation absorption mode is various, has no side effect safely, in mother's breast milk deficiency
And reliable brain nutrition can be provided for premature to the baby in 1 stage one full year of life in the case of other.
Cranial capacity in table 1 to table 3 is all by X-ray or brain CT estimations, all equal zero defects of tested children, growth
Environment is good.
Claims (10)
1. a kind of compound preparation containing two kinds of unrighted acids and sialic acid, it is characterized in that, by weight percentage, compound
Preparation includes the sialic acid of 5%~15%DHA, 10%~20%ARA, 2%~8%, and 2%~5% phosphatidylserine, 1%~
2% antioxidant, 1%~3% acetyl-L-carnitine, 1%~2% choline and auxiliary material.
2. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 1, it is characterized in that,
Also include 1%~3% zinc lactate and 1%~5% taurine.
3. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 1 or 2, its feature
For described auxiliary material is lecithin, beeswax, gelatin, glycerine, one or more mixtures of water.
4. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 1, it is characterized in that,
Described antioxidant is vitamin A, vitamin C, vitamin E, one kind of astaxanthin.
5. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 1, it is characterized in that,
Described antioxidant is astaxanthin.
6. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 3, it is characterized in that,
When described auxiliary material is lecithin, compound preparation is powdery.
7. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 3, it is characterized in that,
When described auxiliary material is water, compound preparation is the aqueous solution.
8. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 3, it is characterized in that,
When described auxiliary material is a variety of mixtures, compound preparation is pasty state or lotion.
9. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 1 or 2, its feature
For with weight ratio meter, DHA and ARA content is 1 in compound preparation：2.
10. a kind of compound preparation containing two kinds of unrighted acids and sialic acid according to claim 1, its feature
For by weight percentage, compound preparation includes 10%DHA, 20%ARA, 4% sialic acid, 2.5% phosphatidylserine, 1%
Antioxidant, 1% acetyl-L-carnitine, 1.5% choline and 60% auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710582418.1A CN107467667B (en) | 2017-07-17 | 2017-07-17 | A kind of compound preparation contained there are two types of unrighted acid and sialic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710582418.1A CN107467667B (en) | 2017-07-17 | 2017-07-17 | A kind of compound preparation contained there are two types of unrighted acid and sialic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107467667A true CN107467667A (en) | 2017-12-15 |
| CN107467667B CN107467667B (en) | 2018-06-26 |
Family
ID=60595127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710582418.1A Active CN107467667B (en) | 2017-07-17 | 2017-07-17 | A kind of compound preparation contained there are two types of unrighted acid and sialic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107467667B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108651996A (en) * | 2018-03-26 | 2018-10-16 | 广东康侨药业有限公司 | A kind of brain tonic and intelligence development alimentation composition and its application |
| CN109601980A (en) * | 2018-11-15 | 2019-04-12 | 嘉必优生物技术（武汉）股份有限公司 | A kind of PUFA soft capsule and preparation method thereof containing sialic acid |
| CN109601677A (en) * | 2019-01-09 | 2019-04-12 | 广州富诺健康科技股份有限公司 | A kind of sialic acid DHA gel candy |
| CN113813252A (en) * | 2021-06-18 | 2021-12-21 | 南京北极光生物科技有限公司 | Omega-3 polyunsaturated fatty acid composition and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259865A (en) * | 1997-03-27 | 2000-07-12 | 布里斯托尔-迈尔斯斯奎布公司 | Use of docosahexanoic acid arachidonic acid enhancing the growth of preterm infants |
| CN1802094A (en) * | 2003-04-14 | 2006-07-12 | 布里斯托尔-迈尔斯斯奎布公司 | Compositions and methods of formulation for enteral formulas containing sialic acid |
| WO2008016743A2 (en) * | 2006-08-02 | 2008-02-07 | Bristol-Myers Squibb Company | Amino acid-based nutritional formulations |
| CN101484025A (en) * | 2006-06-30 | 2009-07-15 | 艾博特公司 | Infant formulas for early brain development |
| CN102458150A (en) * | 2009-06-02 | 2012-05-16 | 雀巢产品技术援助有限公司 | Nutritional composition for supporting brain development and function of toddlers |
| CN103501638A (en) * | 2010-12-31 | 2014-01-08 | 雅培制药有限公司 | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
| CN104968215A (en) * | 2012-12-12 | 2015-10-07 | 罗纳德·罗斯代尔 | Omega-3 fatty acid nutriceutical composition and optimization method |
-
2017
- 2017-07-17 CN CN201710582418.1A patent/CN107467667B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259865A (en) * | 1997-03-27 | 2000-07-12 | 布里斯托尔-迈尔斯斯奎布公司 | Use of docosahexanoic acid arachidonic acid enhancing the growth of preterm infants |
| CN1802094A (en) * | 2003-04-14 | 2006-07-12 | 布里斯托尔-迈尔斯斯奎布公司 | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN101484025A (en) * | 2006-06-30 | 2009-07-15 | 艾博特公司 | Infant formulas for early brain development |
| WO2008016743A2 (en) * | 2006-08-02 | 2008-02-07 | Bristol-Myers Squibb Company | Amino acid-based nutritional formulations |
| CN102458150A (en) * | 2009-06-02 | 2012-05-16 | 雀巢产品技术援助有限公司 | Nutritional composition for supporting brain development and function of toddlers |
| CN103501638A (en) * | 2010-12-31 | 2014-01-08 | 雅培制药有限公司 | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
| CN104968215A (en) * | 2012-12-12 | 2015-10-07 | 罗纳德·罗斯代尔 | Omega-3 fatty acid nutriceutical composition and optimization method |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108651996A (en) * | 2018-03-26 | 2018-10-16 | 广东康侨药业有限公司 | A kind of brain tonic and intelligence development alimentation composition and its application |
| CN109601980A (en) * | 2018-11-15 | 2019-04-12 | 嘉必优生物技术（武汉）股份有限公司 | A kind of PUFA soft capsule and preparation method thereof containing sialic acid |
| CN109601677A (en) * | 2019-01-09 | 2019-04-12 | 广州富诺健康科技股份有限公司 | A kind of sialic acid DHA gel candy |
| CN113813252A (en) * | 2021-06-18 | 2021-12-21 | 南京北极光生物科技有限公司 | Omega-3 polyunsaturated fatty acid composition and preparation method thereof |
| CN113813252B (en) * | 2021-06-18 | 2023-05-09 | 南京北极光生物科技有限公司 | Omega-3 polyunsaturated fatty acid composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107467667B (en) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107467667B (en) | A kind of compound preparation contained there are two types of unrighted acid and sialic acid | |
| CN103687500B (en) | The metabolism trace effect of custom-designed lipid composition | |
| US8007853B2 (en) | Vitamin/mineral composition with DHA | |
| RU2455857C2 (en) | Nutritional composition | |
| US20050037065A1 (en) | Nutritional formulations | |
| CN105558060A (en) | Nutrient-rich pregnant mother milk powder and preparation method thereof | |
| CN107836552A (en) | A kind of DHA gel candies and preparation method thereof | |
| JP2003500445A (en) | Nutritional supplements | |
| CN101088349B (en) | Edible blend oil containing docosahexenoic acid | |
| CN102246863A (en) | Vegetable blended oil for pregnant women and puerperae | |
| CN105188411A (en) | Method of enhancing bioavailability of DHA and other lipid-soluble nutrients | |
| CN109105495A (en) | Baby formula milk powder and preparation method thereof containing choline chloride and L-carnitine | |
| CN102488011A (en) | Formula milk powder containing arachidonic acid for pregnant and parturient women and preparation method thereof | |
| CN104382934A (en) | Multivitamin tablet for pregnant women | |
| CN103191092B (en) | Pharmaceutical composition with effects of supplying calcium and zinc | |
| TW200810762A (en) | Use of DNA and ARA in the preparation of a composition for the prevention or treatment of anemia | |
| CN105188414A (en) | Methods of stimulating infant lung and gut maturation | |
| Miedziaszczyk et al. | The safety of a vegan diet during pregnancy | |
| CN114271335A (en) | Dairy product and method for producing the same | |
| CN107467673B (en) | A kind of compound preparation contained there are three types of unrighted acid and zinc | |
| US20230263736A1 (en) | Soft gelatin capsules | |
| CN107519198A (en) | A kind of iron dextran injection and preparation method thereof | |
| CN107789444A (en) | A kind of bright hair vitamine soft capsule prescription of pet dog and preparation method thereof | |
| RU2311038C2 (en) | Product for enteral feeding | |
| CN108851058A (en) | A kind of multivitamin minerals soft capsule and preparation method thereof rich in alpha-linolenic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230419 Address after: Room 711, Zone C, 2nd Floor, Zhongguancun Dongsheng Science and Technology Park, No.18 Xueqing Road, Haidian District, Beijing, 100000 Patentee after: Beijing Special Medical Internet Biotechnology Co.,Ltd. Address before: 504, 5th Floor, Building 3, Fuhai Center, Daliushu, Haidian District, Beijing, 100080 Patentee before: Beijing Ebany Biological Medicine Technology Co.,Ltd. |